Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.43 |
| ▸ | NNMT | P40261 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5856813 | 0.85 | PPARG (0.39) | ACACBCPB2MAPTFFAR1 | |
| SCHEMBL6266694 | 0.84 | CPB2 (0.39) | KDM4EALDH1A1CPB2MAPTLMNA | |
| SCHEMBL6262756 | 0.83 | ACACB (0.46) | ACACBNNMTKDM4EALDH1A1MEN1 | |
| SCHEMBL5859238 | 0.83 | PPARG (0.38) | ACACBCPB2MAPTFFAR1 | |
| SCHEMBL6263178 | 0.82 | ACACB (0.45) | ACACBNNMTOXTRKDM4ECPB2 | |
| SCHEMBL27956494 | 0.80 | JAK2 (0.45) | NNMTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2431295 | 0.79 | LDHA (0.53) | ACACBKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL3861143 | 0.78 | ACACB (0.44) | ACACBNNMTKDM4EALDH1A1CPB2 | |
| SCHEMBL7945973 | 0.78 | ACACB (0.44) | ACACBNNMTKDM4EALDH1A1CPB2 | |
| SCHEMBL23482186 | 0.78 | ACACB (0.42) | ACACBNNMTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592421-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGAV, ITGA6 | ACACB 2106/4885NNMT 4585/4885OXTR 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.